Bluejay_primary_logo.png
Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress
June 05, 2024 08:00 ET | Bluejay Therapeutics
100% of treated patients in Arm 1 achieved virologic response by Week 28 Most patients also achieved ALT normalization and composite response BJT-778 was well tolerated across all arms at doses...
Bluejay_primary_logo.png
Bluejay Therapeutics Receives Positive Opinion on Orphan Designation from the European Medicines Agency for BJT-778 for the Treatment of Chronic Hepatitis D
May 29, 2024 08:00 ET | Bluejay Therapeutics
SAN MATEO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private clinical-stage biopharmaceutical company focused on viral and liver diseases with unmet medical needs, today...
Bluejay_primary_logo.png
Bluejay Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver (EASL) Congress 2024
May 22, 2024 08:00 ET | Bluejay Therapeutics
SAN MATEO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics today announced it will present new data from its ongoing Phase 2 trial evaluating the potential of BJT-778, an...
Bluejay_primary_logo.png
Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
May 09, 2024 07:00 ET | Bluejay Therapeutics
SAN MATEO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a leader in the development of novel therapeutics, today announced the successful closure of a $182 million Series C...
Bluejay_primary_logo.png
Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection
March 25, 2024 08:00 ET | Bluejay Therapeutics
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a private clinical-stage biopharmaceutical company focused on viral and liver diseases, today announced the European...
Bluejay_primary_logo.png
Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development
September 21, 2023 07:55 ET | Bluejay Therapeutics
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and liver diseases, today announced the...
Bluejay_primary_logo.png
Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment
June 01, 2023 18:14 ET | Bluejay Therapeutics
SAN MATEO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a company dedicated to developing innovative treatments for viral and liver diseases, announces the successful completion...
BluejayTx Logo
Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for Treatment of Chronic Hepatitis B and Chronic Hepatitis D
December 01, 2022 08:30 ET | Bluejay Therapeutics
SAN MATEO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics announced today that it received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and...
BlueJayTherapeuticsLogoFNL_sm.jpg
Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis
August 16, 2022 10:54 ET | Bluejay Therapeutics
SAN MATEO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics announced today that it has closed a $41 million Series B round of finance led by Arkin Bio Ventures. This round includes...
BlueJayTherapeuticsLogoFNL_sm.jpg
Bluejay Therapeutics Announces the Appointment of Nancy Shulman, M.D., as Chief Medical Officer
February 02, 2022 08:00 ET | Bluejay Therapeutics
SAN MATEO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private biopharmaceutical company focused on the development of innovative cures for infectious diseases, today announced...